Evidence map›Paper›PMID 26420788›Full record

ArticleJournal of biomolecular screening2016

Development of a Highly Sensitive Cell-Based Assay for Detecting Botulinum Neurotoxin Type A through Neural Culture Media Optimization.

Won S Hong, Hannah M Pezzi, Andrea R Schuster, Scott M Berry, Kyung E Sung, David J Beebe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomolecular screening, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Won S HongDepartment of Biomedical Engineering, University of Wisconsin, Madison, WI, USA Wisconsin Institute for Medical Research and University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Hannah M PezziDepartment of Biomedical Engineering, University of Wisconsin, Madison, WI, USA Wisconsin Institute for Medical Research and University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Andrea R SchusterDepartment of Biomedical Engineering, University of Wisconsin, Madison, WI, USA.
Scott M BerryDepartment of Biomedical Engineering, University of Wisconsin, Madison, WI, USA Wisconsin Institute for Medical Research and University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
Kyung E SungDepartment of Biomedical Engineering, University of Wisconsin, Madison, WI, USA Wisconsin Institute for Medical Research and University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
David J BeebeDepartment of Biomedical Engineering, University of Wisconsin, Madison, WI, USA Wisconsin Institute for Medical Research and University of Wisconsin Carbone Cancer Center, Madison, WI, USA djbeebe@wisc.edu.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Clinical Neuroengineering Training ProgramT32EB011434 · NIBIB · UNIVERSITY OF WISCONSIN-MADISON · PI MEYERAND, MARY E., PEARCE, ROBERT A · 2011 to 2015
$869k
NCI NIH HHS P30 CA014520NIBIB NIH HHS T32 EB011434
6 · The paper itself

Abstract

Botulinum neurotoxin (BoNT) is the most lethal naturally produced neurotoxin. Due to the extreme toxicity, BoNTs are implicated in bioterrorism, while the specific mechanism of action and long-lasting effect was found to be medically applicable in treating various neurological disorders. Therefore, for both public and patient safety, a highly sensitive, physiologic, and specific assay is needed. In this paper, we show a method for achieving a highly sensitive cell-based assay for BoNT/A detection using the motor neuron-like continuous cell line NG108-15. To achieve high sensitivity, we performed a media optimization study evaluating three commercially available neural supplements in combination with retinoic acid, purmorphamine, transforming growth factor β1 (TGFβ1), and ganglioside GT1b. We found nonlinear combinatorial effects on BoNT/A detection sensitivity, achieving an EC50 of 7.4 U ± 1.5 SD (or ~7.9 pM). The achieved detection sensitivity is comparable to that of assays that used primary and stem cell-derived neurons as well as the mouse lethality assay.

Indexed as

AnimalsBiological AssayBotulinum Toxins, Type ACell Line, TumorCulture MediaEmbryonic Stem CellsGangliosidesMiceMorpholinesMotor NeuronsNeurotoxinsPurinesRatsSensitivity and SpecificityTransforming Growth Factor beta1TretinoinBotulinum Toxins, Type ACulture MediaGangliosidesMorpholinesNeurotoxinsPurinespurmorphamineTransforming Growth Factor beta1Tretinointrisialoganglioside GT1botulinum neurotoxincell-based assaysmedia optimizationtoxicology

Identifiers

PMID26420788
PMCPMC6988902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.